• Sushila Gahlot Gian Sagar Medical College and Hospital, Ramnagar, Rajpura.Punjab
  • P K Prasher Mullana institute of Medical Sciences and Research, Ambala, Haryana.
  • Jaspreet Takkar Gian Sagar Mediccal College and Hospital,Ramnagar,Rajpura,Patiala.


Objective: Many people who have severe chronic kidney disease (CKD) will eventually develop kidney failure and will require dialysis. The control
of parathormone (PTH), phosphorus, and calcium metabolism is one of the objectives in an adequate dialysis protocol. Therefore, we conducted
this study to describe alterations in PTH, calcium, and phosphorous homeostasis in patients with CKD on hemodialysis in our center. Our study also
aimed to find an association between hormonal and biochemical abnormalities in CKD patients, who have been on hemodialysis for ≥5 months and
comparing the results obtained with that recommended by Kidney Disease Improving Global Outcomes (KDIGO) guidelines.

Methods: This was a hospital-based cross-sectional observational study. The study population of 330 patients (>18 years) on maintenance
hemodialysis coming to dialysis Unit of Department of Medicine of Gian Sagar Hospital, Ramnagar (Patiala), over a period of 3 years (2012-2015),
were enrolled in the study. Each patient was considered only once for the study. In addition, biochemical analysis of serum intact PTH (iPTH), corrected
calcium, phosphorus, total alkaline phosphatase (tALP), serum creatinine, blood urea, serum albumin, and hemoglobin of all cases was done using
fully automated equipment. All statistical analyses were performed using SPSS statistical software, version 17.

Results: The study population of 330 patients comprised adults, mainly illiterate (54.5%) predominantly belonging to the rural (66.4%) strata with
a mean age of 52.67±15.05 (range: 25-98 years). The abnormality in the laboratory profile of the patients was found to be hyperparathyroidism in
40.3% as compared to hypoparathyroidism in 33.5% and normal iPTH levels in 26.2%. Hypocalcaemia was detected in 50.6% and hyperphosphatemia
in 62.1% of the patients. There was statistically significant association of serum iPTH, with corrected calcium and phosphorus (P=0.032 and P=0.035,
respectively). Corrected calcium was also significantly associated with phosphorus (P=0.001) and tALP (P=0.007).

Conclusion: We showed in the present study that disorders of mineral metabolism are common in hemodialysis patients and that only a small
proportion adheres to the targets as advised in the KDIGO guidelines for bone metabolism and disease in CKD. We demonstrated that these disorders
are associated with important negative clinical outcomes, such as increased all-cause lack survival, more muscle and bone problems. Our findings,
therefore, support a strict control of mineral metabolism in dialysis patients. Further research and progress in this area are required to establish a
more rational approach with a view toward improving patient outcomes.

Keywords: Parathormone, Calcium, Phosphorus, Hemodialysis.


Author Biographies




Sushila Gahlot, Gian Sagar Medical College and Hospital, Ramnagar, Rajpura.Punjab
Professor & Head, Department of Physiology,
P K Prasher, Mullana institute of Medical Sciences and Research, Ambala, Haryana.
Professor,Department of Medicine


1. Noordzij M, Korevaar JC, Boeschoten EW, Dekker FW, Bos WJ, Krediet RT; Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD) Study Group. The Kidney Disease Outcomes Quality Initiative (K/DOQI) Guideline for Bone Metabolism and Disease in CKD: Association with mortality in dialysis patients. Am J Kidney Dis 2005;46:925-32.
2. Komaba H, Tanaka M, Fukagawa M. Treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Intern Med 2008;47:989-94.
3. Shopit A, Al-Adhal A, Sheiban AK, Amood M, Al-Kamarany. Effect of calcium, alfacalcidol and hemodialysis on secondary hyperparathyroidism. Int J Pharm Pharm Sci 2014;6 Suppl 2:267-72.
4. Brandenburg VM, Floege J. Adynamic bone disease-bone and beyond. NDT Plus 2008;1:135-47.
5. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009;S1-130.
6. Uhlig K, Berns JS, Kestenbaum B, Kumar R, Leonard MB, Martin KJ, et al. KDOQI US commentary on the 2009 KDIGO clinical practice guideline for the diagnosis, evaluation, and treatment of CKD-mineral and bone disorder (CKD-MBD). Am J Kidney Dis 2010;55(5):773-99.
7. National Kidney Foundation. Kidney Disease Improving Global Outcomes; KDIGO 2012. Clinical practice guideline for the evaluation and management of chronic kidney disease. J Int Soc Nephrol 2013;3(1):4-17. Available from:
8. Okoye JU, Arodiwe EB, Ulasi II, Ijoma CK, Onodugo OD. Prevalence of CKD-MBD in pre-dialysis patients using biochemical markers in Enugu, South-East Nigeria. Afr Health Sci 2015;15:941-8.
9. Seck SM, Dahaba M, Ka EF, Cisse MM, Gueye S, Tal AO. Mineral and bone disease in black african hemodialysis patients: A report from senegal. Nephrourol Mon 2012;4:613-6.
10. Maxine A, Papadakis M, Stephen J, McPhess M. Current Medical Diagnosis and Treatment. 52nd ed. New York: The McGraw-Hill Companies; 2013.
11. Ramadaniati HU, Anggriani Y, Wowor VM, Rianti A. Drug-related problems in chronic kidneys disease patients in an Indonesian hospital: Do the problems really matter? Int J Pharm Pharm Sci 2016;8(12):298-302.
12. Agarwal SK, Dash SC, Irshad M, Raju S, Singh R, Pandey RM. Prevalence of chronic renal failure in adults in Delhi, India. Nephrol Dial Transplant 2005;20(8):1638-42.
13. Prasad YS, Murthy HA. Clinical and Biochemical spectrum of chronic kidney disease in tertiary care center. J Evol Med Dent Sci 2012;1(6):1214-22.
14. Valson AT, Sundaram M, David VG, Deborah MN, Varughese S, Basu G, et al. Profile of incident chronic kidney disease related-mineral bone disorders in chronic kidney disease Stage 4 and 5: A hospital based cross-sectional survey. Indian J Nephrol 2014;24(2):97-107.
15. Craver L, Marco MP, Martínez I, Rue M, Borràs M, Martín ML, et al. Mineral metabolism parameters throughout chronic kidney disease stages 1-5 – Achievement of K/DOQI target ranges. Nephrol Dial Transplant 2007;22:1171-6.
16. Szeto CC, Kwan BC, Chow KM, Law MC, Li PK. Geriatric nutritional risk index as a screening tool for malnutrition in patients on chronic peritoneal dialysis. J Ren Nutr 2010;20(1):29-37.
17. Gholamhossein RO, Mohammad HD, Mohammad S. Predictive factors foe persistent hyperparathyroidism after kidney transplantation. Arch Iran Med 2005;8(4):295-9.
18. Dousdampanis P, Trigka K, Fourtounas C. Evolution of secondary hyperparathyroidism one year after successful renal transplantation. Hippokratia 2011;15(2):30-2.
19. Kawarazaki H, Shibagaki Y, Fukumoto S, Kido R, Ando K, Nakajima I, et al. Natural history of mineral and bone disorders after living-donor kidney transplantation: A one-year prospective observational study. Ther Apher Dial 2011;15:481-7.
20. Hussain N, Mahmud M, Abbas G, Ansari S, Samoo Z. Do bone mineral metabolism parameters in Chronic Kidney Disease (CKD) patients meet Kdoqi guidelines? A tertiary care hospital-based cross-sectional study. Pak J Med Dent 2015;4(04):7-12.
21. Vhora RS, Munde A, Bale C, Kakrani AL. Correlation of serum parathyroid hormone, with mineral bone disease in chronic kidney disease patients. Med J Dr. D.Y. Patil Univ 2015;8(6):708-12.
22. Onyemekeihia R, Renal osteodystrophy in Benin. A Dissertation Submitted to the National Postgraduate Medical College of Nigeria, Faculty of Internal Medicine, November; 2004.
23. Sanusi AA, Arogundade FA, Oladigbo M, Ogini LM, Akinsola A. Prevalence and pattern of renal bone disease in end stage renal disease patients in Ile-Ife, Nigeria. West Afr J Med 2010;29(2):75-80.
24. Hutchison AJ. Improving phosphate-binder therapy as a way forward. Nephrol Dial Transplant 2004;19 Suppl 1:i19-24.
25. Hutchison AJ, Speake M, Al-Baaj F. Reducing high phosphate levels in patients with chronic renal failure undergoing dialysis: A 4-week, dose-finding, open-label study with lanthanum carbonate. Nephrol Dial Transplant 2004;19(7):1902-6.
26. Ureña Torres P. Clinical experience with cinacalcet HCl. Nephrol Dial Transplant 2004;19 Suppl 5:V27-33.
27. Goodman WG. Medical management of secondary hyperparathyroidism in chronic renal failure. Nephrol Dial Transplant 2003;18 Suppl 3:iii2-8.
28. Kidney Disease: Improving Global Outcomes (KDIGO). Clinical practice guideline update on diagnosis, evaluation, prevention and treatment of CKD-MBD. Open public Review of the draft CKD-MBD guideline update 2016:01-45.
29. Ritz E, Matthias S, Seidel A, Reichel H, Szabo A, Hörl WH. Disturbed calcium metabolism in renal failure – Pathogenesis and therapeutic strategies. Kidney Int Suppl 1992;38:S37-42.
30. Drüeke TB. The pathogenesis of parathyroid gland hyperplasia in chronic renal failure. Kidney Int 1995;48:259-72.
31. Llach F, Bover J. Renal osteodystrophy. In: Brenner BM, editor. The Kidney. Vol. 2. Philadelphia, PA: W. B. Saunders Company; 1996. p. 2187-203.
32. Drueke TB. Hyperparathyroidism in chronic kidney disease. In: De Groot LJ, Chrousos G, Dungan K, Kenneth R, editors. Disease of Bone and Mineral Metabolism, Book-Endotext 2015.
33. Agarwal SK. Assessment of renal bone mineral disorder in naïve CKD patients: A single center prospective study. Indian J Nephrol 2007;17:96.
34. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: Evaluation, classification, and stratification. Am J Kidney Dis 2002;39 2 Suppl 1:S1-266.
305 Views | 402 Downloads
How to Cite
Bansal, B., S. Gahlot, P. K. Prasher, and J. Takkar. “ALTERATIONS IN PARATHORMONE, CALCIUM AND PHOSPHORUS LEVELS IN CKD PATIENTS ON MAINTENANCE HAEMODIALYSIS IN A HOSPITAL SETTING IN PUNJAB.””. Asian Journal of Pharmaceutical and Clinical Research, Vol. 10, no. 4, Apr. 2017, pp. 196-01, doi:10.22159/ajpcr.2017.v10i4.16529.
Original Article(s)